Informations générales (source: ClinicalTrials.gov)
Prediction of the Response Using Dynamic Contrast-enhanced Magnetic Resonance Imaging Before Intra-arterial Chemotherapy in Children With Retinoblastoma (PREDIR)
Observational
Fondation Ophtalmologique Adolphe de Rothschild (Voir sur ClinicalTrials)
janvier 2018
juillet 2026
29 juin 2024
Retinoblastoma is the most frequent intraocular tumor in children and represents 6% of
all pediatric cancers before the age of 5 years-old. The outcome is now excellent with 95
to 97% of 5-years survival rate. Conservative treatments are being more and more used,
and intra arterial chemotherapy is one of the adjuvant treatments proposed to the
children. The treatment is efficient in most cases, but a small proportion of children
will have an early progression after treatment. MRI is used for the diagnosis of
retinoblastoma. We aim to find prognostic factors using dynamic contrast-enhanced
magnetic resonance imaging (DCE-MRI) for early identification of children response to
intra arterial chemotherapy.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HOPITAL FONDATION A. DE ROTHSCHILD | Augustin LECLER | 21/06/2024 13:30:37 | Contacter | ||
Critères
Tous
Inclusion Criteria:
- grade B to D retinoblastoma
- prescription of intra arterial chemotherapy
- grade B to D retinoblastoma
- prescription of intra arterial chemotherapy
- none